1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow Refractory Neoplasm: new trials by email Literature Review of Refractory Neoplasm trials Research Report on Refractory Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. 9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm | Phase 1 | Terminated | Actuate Therapeutics Inc. | 40 | 2020-06-05 | 2025-07-17 |
Diffuse Intrinsic Pontine Glioma (1) · Meningioma (1) · Neoplasms (1) · Neuroblastoma (1)
Brain Diseases (1) · Brain Neoplasms (1) · Brain Stem Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Infratentorial Neoplasms (1) · Meningeal Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neoplasms, Vascular Tissue (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Cyclophosphamide (1) · Irinotecan (1) · Temozolomide (1) · Topotecan (1)
United States (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719